Watch a live recording of the "BioCentury this Week" podcast in Boston/Cambridge next week! Plus, meet Korea biotechs looking for cross-border deals. 🗓️Thursday, Nov. 6 at Venture Cafe Cambridge, during KHIDI's K-Blockbuster Night. ✅ RSVP: venturecafecambridge.org/eve…

At the #BioCenturyChinaSummit, we'll discuss how to reinvent your strategy. If you are a China biotech, it is time to reinvent your global strategy. If you are a global biopharma or investor, you must reinvent your China strategy. Advanced rates end soon: loom.ly/plld69k

There is only 1 week left to lock in 2024 rates for the 25th #BioEquityEurope. Finalize your sponsorship package by Sept. 30 before our rates increase Oct. 1. Check out our packages or request a customized proposal: loom.ly/gBdm0vo Learn more: bioequityeurope.com.

On the latest episode of the #BioCenturyThisWeek podcast: ➤ Biotech IPOs: Bicara, MBX, & Zenas debut on NASDAQ ➤ GLP-1s vs. PD-1s: Will obesity drugs mirror cancer trends? ➤ AI's growing impact on biopharma Tune in on your favorite podcast platform: loom.ly/-zyZ4WY

Spots are now SOLD OUT for the #BioCenturyGrandRounds poster session, with 40+ early stage biotechs and academic innovators selected by BioCentury to share their science at the conference in Nashville. Register and learn more at biocenturygrandrounds.com.

Industry KOLs at #BioCenturyGrandRounds will discuss new targets, biomarkers, and advanced tools like EEG & fMRI for treating neurodegenerative & neuropsychiatric diseases in this panel on multi-omics & human data innovation. Learn more: biocenturygrandrounds.com

BioCentury and BayHelix will bring the 4th East-West Biopharma Summit back to Singapore in March 2025. Please join us for this exclusive event designed for VCs and #biopharma decision-makers. Register for #BioCenturyEastWest with early bird rates: loom.ly/WqidFHU

To help frame the discussion at #BioCenturyGrandRounds, Insights Partner @McKinsey will unveil an exclusive conference report examining the current state of biopharma research and forecasts where translation is headed. View the full agenda and register: biocenturygrandrounds.com

Join R&D thought leaders in Nashville, Sept. 9-11 at #BioCenturyGrandRounds. Discuss critical bottlenecks in translation and explore the next wave of biotech breakthroughs with pharmas, VCs, and academic innovators. Advanced rates end Aug. 2. Register at biocenturygrandrounds.com.

Greg Verdine, Co-Founder, President & CEO of LifeMine Therapeutics and Professor of Chemistry at Harvard University is joining #BioCenturyGrandRounds to deliver a keynote address: Blowing up the small molecule paradigm. Learn more: loom.ly/yydzbC8